[go: up one dir, main page]

MX2018001052A - Metodos para reducir la necesidad de cirugia en pacientes que padecen hiperplasia prostatica benigna. - Google Patents

Metodos para reducir la necesidad de cirugia en pacientes que padecen hiperplasia prostatica benigna.

Info

Publication number
MX2018001052A
MX2018001052A MX2018001052A MX2018001052A MX2018001052A MX 2018001052 A MX2018001052 A MX 2018001052A MX 2018001052 A MX2018001052 A MX 2018001052A MX 2018001052 A MX2018001052 A MX 2018001052A MX 2018001052 A MX2018001052 A MX 2018001052A
Authority
MX
Mexico
Prior art keywords
need
surgery
patients
methods
reduce
Prior art date
Application number
MX2018001052A
Other languages
English (en)
Other versions
MX385860B (es
Inventor
Averback Paul
Original Assignee
Nymox Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Corp filed Critical Nymox Corp
Publication of MX2018001052A publication Critical patent/MX2018001052A/es
Publication of MX385860B publication Critical patent/MX385860B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Las realizaciones incluyen métodos para tratar afecciones que requieren la eliminación o destrucción de elementos celulares, tales como tumores benignos o malignos que usan compuestos basados en péptidos pequeños en combinación con agente (s) activo (s) adicional (es). El método incluye, pero no se limita a, administrar los compuestos intramuscularmente, oralmente, intravenosamente, intratecalmente, intratumoralmente, intranasalmente, tópicamente, transdérmicamente, etc., solos o conjugados a un vehículo a un mamífero que lo necesite. Llevar a cabo el método de forma inesperada reduce la necesidad de una intervención quirúrgica invasiva posterior.
MX2018001052A 2015-07-24 2016-07-25 Peptido para usarse para reducir la necesidad de cirugía en pacientes que tienen hiperplasia prostática beningna. MX385860B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/808,731 US11628202B2 (en) 2015-07-24 2015-07-24 Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
PCT/US2016/043850 WO2017019593A1 (en) 2015-07-24 2016-07-25 Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia

Publications (2)

Publication Number Publication Date
MX2018001052A true MX2018001052A (es) 2018-11-09
MX385860B MX385860B (es) 2025-03-04

Family

ID=56682253

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001052A MX385860B (es) 2015-07-24 2016-07-25 Peptido para usarse para reducir la necesidad de cirugía en pacientes que tienen hiperplasia prostática beningna.

Country Status (17)

Country Link
US (1) US11628202B2 (es)
EP (1) EP3324994B1 (es)
JP (1) JP6884134B2 (es)
KR (1) KR20180037986A (es)
CN (1) CN108025037A (es)
AU (1) AU2016297890B2 (es)
BR (1) BR112018001533A2 (es)
CA (1) CA2993548A1 (es)
DK (1) DK3324994T3 (es)
ES (1) ES2872730T3 (es)
HU (1) HUE054137T2 (es)
LT (1) LT3324994T (es)
MX (1) MX385860B (es)
PL (1) PL3324994T3 (es)
PT (1) PT3324994T (es)
SI (1) SI3324994T1 (es)
WO (1) WO2017019593A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10532081B2 (en) * 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) * 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
US10835538B2 (en) 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics
US20200061150A1 (en) * 2018-08-23 2020-02-27 Nymox Corporation Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
US11278588B2 (en) 2019-05-13 2022-03-22 Nymox Corporation Method of treating lower urinary tract symptoms with fexapotide triflutate
US20200360466A1 (en) 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US11331374B2 (en) 2019-07-31 2022-05-17 Nymox Corporation Focal treatment of prostate cancer
US11231421B2 (en) 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer
EP4472743A4 (en) * 2022-02-04 2025-11-19 Hbc Immunology Inc MEDICINAL USES OF OLIGOPEPTIDES IN COMBINATION WITH AN ANTIANDROGEN

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948634A (en) 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
ES2094733T3 (es) 1988-12-21 1997-02-01 Gen Hospital Corp Deteccion de enfermedades o disfunciones neurologicas.
JPH06256387A (ja) 1991-06-14 1994-09-13 Suetsuna Yoko 新規なペプチド、その製法およびそれを有効成分とする 血圧降下剤
NZ266072A (en) 1993-04-20 1997-07-27 Gen Hospital Corp Neural thread protein and its use in detecting alzheimers, neuroectodermal tumours, malignant astrocytomas and glioblastomas
US6660830B1 (en) 1996-03-26 2003-12-09 Razvan T Radulescu Peptides with antiproliferative properties
CA2282729A1 (en) 1997-02-26 1998-09-03 The General Hospital Corporation Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease
WO1999019347A1 (en) 1997-10-10 1999-04-22 Astrazeneca Ab Synthetic genes with immunomodulatory effects
EP1135494A2 (en) 1998-12-11 2001-09-26 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
WO2000063230A2 (en) 1999-03-26 2000-10-26 Human Genome Sciences, Inc. 49 human secreted proteins
JP2002542766A (ja) 1999-03-12 2002-12-17 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５０個のヒト分泌タンパク質
AU3628600A (en) 1999-03-19 2000-10-09 Human Genome Sciences, Inc. 46 human secreted proteins
CA2368927A1 (en) 1999-03-26 2000-10-05 Craig A. Rosen 45 human secreted proteins
AU3765500A (en) 1999-03-26 2000-10-16 Human Genome Sciences, Inc. 50 human secreted proteins
CN1300779A (zh) 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人神经元线蛋白17和编码这种多肽的多核苷酸
JP2001264442A (ja) * 2000-03-22 2001-09-26 Fuji Photo Film Co Ltd 画像記録媒体
AU2001271455A1 (en) 2000-06-26 2002-01-08 Millennium Pharmaceuticals, Inc. A human calcium channel protein and uses thereof
US7259232B1 (en) 2000-10-27 2007-08-21 Nymox Pharmaceutical Corporation Preferred segments of neural thread protein
CA2325666A1 (fr) 2000-12-01 2002-06-01 Institut Pasteur Peptides immunogeniques mutes derives de r9m, polynucleotides les codants et leurs usages therapeutiques
US6783969B1 (en) 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
DE60222745T2 (de) 2001-03-08 2008-07-10 Nymox Pharmaceutical Corp., St. Laurent Verwendung von neurofilamentproteinen zur behandlung von tumoren
KR20040008177A (ko) 2001-05-16 2004-01-28 니목스 코포레이션 신경 사 단백질 세그먼트를 사용하여 세포 사멸을억제하는 방법
DE60217326T2 (de) 2001-05-25 2007-10-18 Nymox Corp., Saint-Laurent Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung
IL159903A0 (en) 2001-07-19 2004-06-20 Nymox Corp Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
WO2005113720A2 (en) 2004-05-19 2005-12-01 Auburn University A strategy for designing patient-specific anti-cancer drugs
MX2008010942A (es) 2006-02-28 2008-09-03 Nymox Corp Peptidos efectivos en el tratamiento de tumores y otras condiciones que requieren la remocion o destruccion de celulas.
EA200801942A1 (ru) * 2006-03-10 2009-02-27 Наймокс Корпорейшн Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон
US9243035B2 (en) 2013-11-26 2016-01-26 Nymox Corporation Peptides effective in the treatment of conditions requiring the removal or destruction of cells
US20160215031A1 (en) 2015-01-27 2016-07-28 Nymox Pharnaceutical Corporation Method of treating disorders requiring destruction or removal of cells
JP6256387B2 (ja) 2015-03-09 2018-01-10 株式会社豊田自動織機 電動圧縮機
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations

Also Published As

Publication number Publication date
HUE054137T2 (hu) 2021-08-30
WO2017019593A1 (en) 2017-02-02
EP3324994B1 (en) 2021-04-14
EP3324994A1 (en) 2018-05-30
JP2018520200A (ja) 2018-07-26
AU2016297890A1 (en) 2018-02-15
HK1249007A1 (zh) 2018-10-26
MX385860B (es) 2025-03-04
US11628202B2 (en) 2023-04-18
US20170020957A1 (en) 2017-01-26
BR112018001533A2 (pt) 2019-02-12
DK3324994T3 (da) 2021-04-26
PL3324994T3 (pl) 2021-08-16
LT3324994T (lt) 2021-05-25
AU2016297890B2 (en) 2021-08-19
SI3324994T1 (sl) 2021-08-31
KR20180037986A (ko) 2018-04-13
CN108025037A (zh) 2018-05-11
NZ739292A (en) 2024-05-31
ES2872730T3 (es) 2021-11-02
CA2993548A1 (en) 2017-02-02
JP6884134B2 (ja) 2021-06-09
PT3324994T (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
MX2018001052A (es) Metodos para reducir la necesidad de cirugia en pacientes que padecen hiperplasia prostatica benigna.
MX383809B (es) Composiciones de combinacion para tratar trastornos que requieren de la remocion o destruccion de proliferaciones celulares no deseadas.
MX2019010757A (es) Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
MX387788B (es) Uso de agentes activos durante tratamientos quimicos.
CO2018001375A2 (es) Composiciones de retinoides tópicos
MX2018012486A (es) Composiciones para aplicacion topica de compuestos.
CO6300964A2 (es) Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano
MX2013011721A (es) Metodos para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.
MX394252B (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
WO2012121977A3 (en) Dodecafluoropentane emulsion as a stroke and ischemia therapy
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
DOP2016000102A (es) (aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso
MX2017009802A (es) Metodo para tratar desordenes que requieren la destruccion o retiro de celulas utilizando un peptido derivado de una proteina de hebra neural.
EP4374873A3 (en) Methods for treating or preventing opthalmological conditions
MX2018000166A (es) Metodos para una mejor administración de agentes activos a tumores.
MX2019014667A (es) Tratamiento de trastornos cutaneos.
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
CL2020000019A1 (es) Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso.
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
CL2015002171A1 (es) Métodos de tratamiento de la dificiencia de hierro con pirofosfato férrico soluble.
BR112019006880A2 (pt) compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos
MX378586B (es) Composición y método para el tratamiento de padecimientos de la piel